October is Breast Cancer Awareness Month, and October 13, 2023 is National Metastatic Breast Cancer Awareness Day. An important month that is recognized by nearly all of the leading professional and patient-facing organizations including advocacy groups representing oncology, women’s health, breast cancer survivors and all the related healthcare professionals. This includes respected organizations like American Society of Clinical Oncology (ASCO), National Comprehensive Cancer Network (NCCN), American Cancer Society (ACS), National Breast Cancer Foundation, Susan G. Komen, Breast Cancer Now, and so many more. 

This is our second in the series, and updates our Breast Cancer Awareness Month 2022 post from last year. For Breast Cancer Month 2023, we will be looking at all of the new guidelines, therapies and innovations on breast cancer screenings and treatment that have been introduced since Breast Cancer Awareness Month 2022.

Breast Cancer – Clinical Practice Guidelines:

Breast Cancer – FDA Drug Approvals:

There have been three major new FDA approvals for breast cancer diagnostics and treatments since the beginning of 2023:

  • Orserdu (Stemline Therapeutics) – January 26, 2023
    • For postmenopausal women or men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that progressed on at least one line of endocrine therapy.
  • Trodelvy (Gilead) – February 3, 2023
    • For patients with unresectable, locally advanced or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer after endocrine-based therapy and at least two additional systemic therapies for metastatic disease.
  • Verzenio(Eli Lilly) – March 6, 2023
    • In combination with endocrine therapy for patients with hormone receptor (HR)–positive, HER2-negative, node-positive early breast cancer who are at high risk for recurrence.

Looking Ahead:

As we look ahead towards Breast Cancer Awareness Month 2024, we expect multiple upcoming guidelines and guideline updates from the American Society of Clinical Oncology (ASCO). We’re also expecting another update to the National Comprehensive Cancer Network (NCCN) Guidelines for Breast Cancer, since the last update was roughly 6 months ago. 

List of New Guidelines Publications Expected Between 2023 (now) and Breast Cancer Awareness Month 2024 include:

  • NCCN – Breast Cancer
  • ASCO – HR-Positive, HER2-Negative Metastatic Breast Cancer
  • ASCO – Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer
  • ASCO – Use of Endocrine Therapy for Breast Cancer Risk Reduction
  • Sentinel Lymph Node Biopsy for Patients with Early-Stage Breast Cancer
  • ASCO – Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer
  • ASCO – Adjuvant Endocrine Therapy for Breast Cancer
  • ASCO – Germline Mutation Testing in Breast Cancer
  • ASCO – HER2 Testing in Breast Cancer
  • ASCO – Postmastectomy Radiotherapy

The recent updates and guidelines, in the field of breast cancer treatment and screenings provide healthcare professionals a range of new evidence-based resources and approaches to ensure favorable outcomes to all patients.

That’s it for our recap of this year’s recent Breast Cancer Awareness Month 2023.

Copyright © 2023 Guideline Central, All rights reserved.